Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CAN
vs
S
S&P/ASX 300
CAN
Over the past 12 months, CAN has underperformed S&P/ASX 300, delivering a return of -57% compared to S&P/ASX 300's 3% drop.
Stocks Performance
CAN vs S&P/ASX 300
Performance Gap
CAN vs S&P/ASX 300
Performance By Year
CAN vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cann Group Ltd
Glance View
Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.